glp 1 approved for cardiovascular disease Glucagon-like peptide receptor agonists: benefits and mechanisms of action Beyond Blood Sugar: A Scoping

Sensitivity analyses showed that the probability of using GLP-1RAs versus insulin being cost-effective for preventing one case of all-cause mortality or hospitalized hypoglycemia ranged from 60 to 100%

and in July 2024, the FDA approved Kisunla (donanemab) for early symptomatic Alzheimers, based on evidence of reduced clinical decline and a limitedduration regimen tied to amyloid plaque removal

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, including a reduced risk of blindness

This trend is driven by two factors: the growing global demand for tre

New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.